The bill requires the California Health and Human Services Agency to develop recommendations supporting a five-year implementation plan aimed at reducing alcohol- and drug-related addiction deaths by 50% by 2031, with a final recommendations deadline of January 1, 2028. To develop those recommendations the agency must convene an advisory group composed of state health agencies, providers, payers, researchers, consumer representatives, and people with lived experience, and evaluate the best available scientific, medical, technological, and socioeconomic evidence.
After receiving advice, the agency must adopt the recommendations and assess existing health coverage, insurance policies and parity rules affecting substance use disorder treatment. The bill directs the agency to recommend minimum quality and performance standards (including access to low-barrier care, pharmacy and primary-care provision of medications for addiction, provider training, and consideration of comorbidities and disparities) and to report findings, outcomes measures, and continued actions to the Governor and Legislature.
At a Glance
What It Does
Requires the California Health and Human Services Agency to produce recommendations and a five-year implementation plan (deadline: Jan 1, 2028) targeting a 50% reduction in alcohol- and drug-related deaths by 2031, and to adopt those recommendations. It mandates review of coverage and parity, establishment of minimum quality standards, and creation of specific performance metrics.
Who It Affects
State health agencies and regulators, managed care plans and insurers that cover substance use disorder treatment, primary care clinics and pharmacies expected to provide addiction medications, substance use treatment providers, researchers, and communities disproportionately affected by overdose.
Why It Matters
The bill ties an explicit outcome target to a cross-agency planning process and demands concrete coverage and quality assessments that could change how plans and providers deliver treatment, how metrics are tracked, and what statutory or regulatory changes the state pursues to expand access and equity in addiction care.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill sets an outcome goal — halve alcohol- and drug-related addiction deaths by 2031 — and then instructs the state health apparatus to build a realistic path to that goal. It gives the California Health and Human Services Agency until January 1, 2028 to assemble recommendations that form a five-year implementation plan and to convene an advisory group made up of state agencies, payers, providers, researchers, consumer advocates, and people with lived experience.
The bill is explicit that recommendations must distinguish what the state can accomplish under current administrative authority and what will require new regulations or legislation.
In practice, the agency must perform a coverage and policy audit: examine existing health plan benefits, parity compliance, treatment access, and data on outcomes and utilization. The bill directs the agency to identify minimum quality and performance standards for substance use disorder services; illustrative priorities include low-barrier delivery models, pharmacy access to addiction medications, primary care capacity to prescribe and manage medications for addiction, and provider training in evidence-based models.
The agency must also analyze how comorbidities and social determinants — housing, food security, caregiving responsibilities, language, and geography — influence outcomes and where disparities persist.The statute requires interagency consultation to leverage data and purchasing power across entities that regulate or contract for health coverage. Finally, the agency must report to the Governor and Legislature on whether the 2031 goal was met, how effective the advisory group’s recommendations were, and provide recommendations for continuing reductions beyond 2031.
The required report can include established quality sets (for example, HEDIS and federal Core Set measures), CalPERS’ Quality Alignment Measure Set, consumer experience surveys, new outcome metrics, and measures of social determinants of health.Taken together, the bill creates a planning and measurement architecture rather than prescribing specific program expenditures or regulatory text. It establishes a formal process to identify policy levers — legislative, regulatory, coverage, and delivery changes — that the state could deploy to meet an ambitious mortality reduction target.
The Five Things You Need to Know
Deadline and target: the agency must deliver recommendations supporting a five-year plan by January 1, 2028, aimed at cutting alcohol- and drug-related addiction deaths 50% by 2031.
Advisory group composition: required membership includes multiple state health agencies (DHCS, Covered California, CalPERS, DHACI, State Public Health, EMS Authority), providers, insurers, researchers, consumer representatives, and people with lived experience.
Legal vs administrative: recommendations must specify which actions are achievable under existing administrative authority and which would require new regulations or legislation.
Minimum standards focus areas: the agency must consider low-barrier models, pharmacy and primary-care access to addiction medications, provider training in evidence-based medication models, and interaction with comorbidities.
Reporting and metrics: the agency’s report to the Governor and Legislature must assess whether the 2031 goal was met and may include HEDIS and CMS Core Set measures, CalPERS’ Quality Alignment Measure Set, consumer experience surveys, new outcome metrics, and social determinants of health indicators.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Implementation recommendations and advisory group
This subsection charges the Health and Human Services Agency with producing recommendations to underpin a five-year implementation plan and creates the advisory group to advise those recommendations. Practically, the agency must assemble cross-disciplinary expertise and community voices and must document which interventions can be executed administratively versus those that need regulatory or legislative action. This framing forces the advisory process to produce an actionable menu of options, not just high-level goals.
Adoption of recommendations and coverage/quality review
After gathering input, the agency must adopt the advisory group’s recommendations and conduct a systematic review of health coverage, insurance practices, and parity rules affecting substance use disorder treatment. The subsection requires the agency to recommend minimum quality and performance standards, explicitly listing access to low-barrier care, pharmacy and primary-care provision of addiction medication, provider training, and attention to comorbidities and disparities—each of which will have operational implications for payers and providers if adopted.
Interagency consultation
This short provision directs the agency to consult with other state entities that regulate or contract for health coverage so that the recommendations and data analysis reflect purchasing and regulatory realities across state programs. That coordination clause signals the bill expects alignment across DHCS, Covered California, CalPERS, DHACI, public health, and EMS systems when the state evaluates and implements changes.
Reporting requirements and outcome metrics
The agency must report to the Governor and Legislature on whether the 2031 target was achieved and on the effectiveness of the advisory group’s recommendations, while also proposing continued actions beyond 2031. The statute enumerates potential measurement tools and domains—HEDIS, CMS Core Set, CalPERS measures, consumer surveys, new health outcomes metrics, and social determinants indicators—so the report will be both evaluative and prescriptive about future measurement priorities.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- People with substance use disorders and their families — the mandate focuses state planning on expanding low-barrier treatment access, medication availability at pharmacies and primary care settings, and addressing social determinants that impede recovery.
- Communities experiencing disparate overdose rates — the bill requires analysis of race, ethnicity, language, income, geography, and other characteristics, which should surface targeted interventions for underserved populations.
- State purchasers and public health agencies — a standardized set of recommended quality measures and an interagency planning process provide a common framework for contracting and program design that can improve coordination across state-funded programs.
Who Bears the Cost
- California Health and Human Services Agency and participating state agencies — they must devote staff time, data analytics capacity, and convening resources to develop recommendations, run the advisory group, and produce the mandated report.
- Health plans and insurers — they face a formal parity and coverage review and the prospect of new minimum standards or required benefit changes, which could increase administrative and benefit costs.
- Providers, pharmacies, and primary-care clinics — expanding low-barrier models and adding medication-based treatment and training could require investments in workforce, supply chains, and practice redesign, especially for smaller or rural providers.
Key Issues
The Core Tension
The bill balances an urgent, quantifiable public-health goal against a planning-centric approach that lacks guaranteed funding or enforcement: it pushes the state to define what must change but leaves the politically hardest steps—mandating coverage changes, securing provider capacity, and financing expanded services—for future implementation decisions.
The bill ties an ambitious, outcome-based target to a planning and measurement process but stops short of allocating funding or creating enforceable coverage mandates. That design makes success dependent on downstream decisions: recommendations alone will not change insurance benefits or expand provider capacity without follow-up regulatory action, legislation, or new funding.
The requirement to distinguish between actions achievable administratively and those needing legislation is practical, but it also creates a two-track process where high-impact changes may be delayed pending separate legislative action.
Measurement and attribution will present real challenges. Choosing which metrics to use (HEDIS, CMS Core Set, CalPERS measures, new outcome measures) affects conclusions about progress and could privilege measures that are easier to collect over those that more accurately capture equity and long-term recovery.
Data gaps—especially for uninsured populations, undocumented residents, and smaller providers—will limit the agency’s ability to assess outcomes across all communities. Finally, the bill emphasizes access and quality but leaves unanswered how to resolve provider shortages, reimbursement rates, or legal/regulatory barriers that impede pharmacies and primary care from delivering medications for addiction at scale.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.